Go offline with the Player FM app!
Combining an Antibody and siRNA to Treat Hepatitis B
Manage episode 468579950 series 49047
More than a decade after the approval of a curative therapy for hepatitis C, hepatitis B has proven more challenging to tackle. Vir Biotechnology, in collaboration with Alnylam Pharmaceuticals, is developing a promising combination approach that marries Vir’s monoclonal antibody tobivibart with Alnylam’s siRNA elebsiran. We spoke to Mark Eisner, chief medical officer of Vir, about hepatitis B, the company’s combination therapy in development with Alnylam, and its platform technologies for developing treatments for infectious disease and oncology.
565 episodes
Manage episode 468579950 series 49047
More than a decade after the approval of a curative therapy for hepatitis C, hepatitis B has proven more challenging to tackle. Vir Biotechnology, in collaboration with Alnylam Pharmaceuticals, is developing a promising combination approach that marries Vir’s monoclonal antibody tobivibart with Alnylam’s siRNA elebsiran. We spoke to Mark Eisner, chief medical officer of Vir, about hepatitis B, the company’s combination therapy in development with Alnylam, and its platform technologies for developing treatments for infectious disease and oncology.
565 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.